Key facts
- Belhaven Biopharma’s last known valuation is $138.7M (Oct 2025).
- It has raised $51.2M across 1 recorded rounds; the latest was Early Stage VC ($32.3M) in Aug 2025.
- Notable investors include Xcendra Ventures.
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Belhaven Biopharma
Funding rounds
1 roundsAbout Belhaven Biopharma
Developer of a life-saving medication designed for the treatment of anaphylaxis. The company is developing a portfolio of dry powder nasal medicines to provide convenient, safe, and rapid treatments in emergencies, enabling patients to get quick treatment.
- Sector
- Healthcare
- HQ
- Raleigh, NC, United States
- Founded
- 2020
- Employees
- 3
- Website
- belhavenbio.com/
- Ownership
- Privately Held (backing)
Belhaven Biopharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Belhaven Biopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Belhaven Biopharma in its N-PORT filings yet. We sweep new filings monthly.